154 results about "Single amino acid" patented technology

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.

The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

The invention discloses a preparation method and application for cigarette flavor. The preparation method for the cigarette flavor comprises the following steps: a single amino acid is selected, or a few single amino acids are compounded, and the amino acids are mixed with a saccharide substance according to certain proportion to react under certain conditions to obtain a Maillard reaction liquid product, namely the cigarette flavor. The cigarette flavor obtained by the preparation method has certain improvement on the smoking smell of shredded tobacco, ensures that the smoking fragrance is plumper, reduces smoking miscellaneous gas and the irritation of smoke gas, and improves the sense of comfort.

The present invention provides RecA mutant proteins, having either a single mutation or a double mutation. The RecA mutant proteins are highly proficient in both SSB displacement and steady state binding of DNA in the presence or absence of SSB as compared to the wild-type protein. The single RecA mutant, RecAΔC17, has 17 amino acid residues removed from the carboxyl terminus. The double mutant RecA, RecAΔC17 / E38K, combines the 17 amino acid residue C-terminal deletion of RecAΔC17, with a single amino acid change from Glutamate to Lysine at position 38. These RecA mutant proteins are pH sensitive allowing control over formation of products. Hence, methods of using the novel RecA mutants and kits having the RecA mutants as components thereof are also contemplated by the present invention.

Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.

Single amino acid compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The single amino acid compounds may be used in compositions and methods to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals.

The present invention relates to a purified, easily produced poly-beta-1->4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a beta-1->4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and / or its reformulations.

An engineered highly specific DNA-cleavage enzyme delivers a site-specific nick in a double stranded DNA, to cleave one DNA strand within its target site while leaving the opposing DNA strand intact. The engineered enzyme provides the ability to induce a gene conversion event in a mammalian cell. An engineered sequence-specific nickase derived from a LAGLIDADG homing endonuclease is altered by a single amino acid residue, wherein the amino acid residue is involved in the polarization of solvent molecules and acid-base catalysis in the active site without affecting direct contacts between the enzyme and either the bound DNA or bound metal ions. Engineered, site-specific nickase variants, such as of I-AniI and other homing endonucleases, are particularly useful in targeted genome engineering as well as therapeutic, targeted gene repair.

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

The invention relates to a method for preparing Semaglutide through solid and liquid combination, and solves the technical problems that in the process for synthesizing long-sequence polypeptide by the existing technology, the synthesis period is long; the purification difficulty is high; the yield is low. The method for preparing Semaglutide through solid and liquid combination provided by the invention is characterized in that firstly, Lys and resin are condensed in an Alloc-Lys(Fmoc)-OH form by adopting a solid phase synthesis method; Fmoc protecting groups on epsilon-NH2 are removed; sidechain connection is performed; cracking is performed to obtain Alloc-Lys(PEG-PEG-gamma-Glu(OtBu)-Monobutyl octadecanate)-OH; meanwhile, 10 dipeptide or tripeptide or tetrapeptide fragments are simultaneously synthesized by a liquid phase synthesis method; then, the condensation reaction of the synthesized peptide fragments and single amino acid is performed by using the resin as a carrier; the 15-step solid phase condensation reaction is reduced in the process; the generation of lacked peptide impurities is reduced; the product purity and the yield are improved; meanwhile, the generation of the impurities of [+Gly]-Semaglutide and [+Ala]-Semaglutide is effectively avoided; the purification difficulty is greatly reduced. The method is widely applied to the technical field of polypeptide medicine preparation.

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and / or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and / or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.

The invention discloses a fleshy duck fodder and a preparation method thereof. The fleshy duck fodder comprises the following components in parts by weight: 50 to 65 parts of corn, 12 to 25 parts of fine rice bran, 2.5 to 12 parts of cotton dregs, 2 to 12 parts of rapeseed meal, 1 to 6 parts of corn alcohol dregs, 0.5 to 2 parts of corn oil, 0.5 to 2 parts ns of rock powder, 0.2 to 1.5 parts of calcium phosphate secondary, 0.1 to 0.6 part of common salt, 0.2 to 0.8 part of lysine with the consistence of 65%, 0.05 to 0.25 part of methionine, 0.04 to 0.2 part of threonine, 0.01 to 0.1 part of tryptophan, 0.05 to 0.2 part of miscellaneous meal enzyme and 0.5 to 2 parts of premix compound. In the fodder, bean dregs are replaced by the cotton dregs and rapeseed meal, single amino acid and miscellaneous meal enzyme are added, the feed costs of fleshy ducks are greatly reduced, the feed effect to the fleshy ducks is better than the fodder with the bean dregs, the production performance of the fleshy ducks can be obviously enhanced, and the invention has the advantages of wide resources of raw materials, low production cost, high feed efficiency, and the like.

Synthetic amino acids containing one or more non-fouling groups or moieties are described herein. In one embodiment, the amino acid has the following chemical formula:where L is a linker group and Z is a non-fouling group including, but not limited to, polyethylene glycol (PEG); oligoethylene glycol (OEG); zwitterionic group, such as phosphorycholine, carboxybetaine, and sulfobetaine; groups that are hydrogen bond acceptors but not hydrogen bond donors. The non-fouling amino acids can be incorporated into a bioactive peptide as single amino acid residues, multiples amino acid residues, or as blocks of amino acids. The non-fouling amino acids, or peptides containing one or more non-fouling amino acids, can be applied to surfaces in order to improve biocompatibility, reduce thrombogenesis, and / or reduce fouling by proteins or bacteria present in solution.

The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and / or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and / or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.

The invention relates to a protein secondary structure prediction method based on deep neural networks. According to the method, the mutual dependence characteristics of protein sequences can be fusedthrough a plurality of different levels of convolutional neural networks. Meanwhile, single amino acid characteristics are extracted at the same time. The characteristics are input into a recurrent neural network to be further fused, and mapping relations with eight categories of protein are established through a full connection layer. Finally, an RMSProp optimizer is used for training the deep neural network based on the cross entropy error between labels and logits, so that the prediction accuracy of the protein secondary structure is effectively improved.

The invention belongs to the technical field of fertilizer production, and specifically discloses an environment-friendly ecological full-nutrient fertilizer and a production method of the fertilizer. The environment-friendly ecological full-nutrient fertilizer comprises raw materials in parts by weight as follows: 10-50 parts of urea, 5-25 parts of ammonium sulfate, 10-40 parts of monoammonium phosphate, 10-40 parts of potassium chloride or potassium sulfate, 5-10 parts of plant straw ash, 1-10 parts of an active nitrogen source, 0.1-0.5 part of an active carbon source and 5-20 parts of a filler, wherein the active nitrogen source is single amino acid or compound amino acid, the active carbon source is a mixture of glucose and vitamin C in a weight ratio of 1: (0.5-4), and the plant straw ash is the straw ash of plants applying the fertilizer. The full-nutrient fertilizer has the characteristics of organic-inorganic combination and environmental protection, the output increase is obvious, and the utilization rate of the fertilizer is increased.

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid analgesic. The methods comprise orally administering an opioid prodrug or pharmaceutically acceptable salt thereof to a subject, wherein the opioid pro-drug is comprised of an opioid analgesic covalently bonded through a carbamate linkage to a prodrug moiety, and wherein upon oral administration, the prodrug or pharmaceutically acceptable salt minimizes at least one gastrointestinal side effect associated with oral administration of the opioid analgesic alone. Compositions for use with the method are also provided.

The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and / or its reformulations.

The invention belongs to the technical field of functional polypeptides and discloses a collagen polypeptide rich in glycine and a formaldehyde scavenger prepared therefrom. The collagen polypeptide is prepared from the following steps: extracting collagens by means of a hot water extraction method; and then preparing the collagen polypeptide rich in glycine by enzymolysis of the collagens by means of protease by taking Tilapia mossambica waste as a raw material. By being combined with plant polyphenol compounds, the quick, long-acting, safe and edible formaldehyde scavenger is prepared. The formaldehyde removal rate of the formaldehyde scavenger can reach 95% or above within 10 min, so that the problem that a single amino acid is not ideal in removing formaldehyde is solved. A colloid film which is 2-10 microns can be formed on the surface of an object such as furniture if being dried to inhibit further release of formaldehyde. The formaldehyde removal rate can be kept at 95% or abovewithin three months, an effect of removing formaldehyde for a long time is achieved, and the problem that existing formaldehyde removal products are rebound in effect and short in effective period issolved.

The present invention relates to a purified, easily produced poly-beta-1->4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a beta-1->4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and / or its reformulations.

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

The invention provides a rapid estimation method for determining the synthesis proportion and the chelation rate of a microelement chelate through combination of a spectrophotometric method and an XRD (X-ray diffraction) technology. The method provided by the invention is suitable for determining an appropriate material ratio when a complex is synthesized by compound amino acid / small peptides and transition metal ions; meanwhile, the content of microelement inorganic salt in any organic microelement chelate product can be detected rapidly and accurately, so that the chelation rate of the product can be further estimated. The method is rapid in implementation, strong in applicability and simple in operation, and has the practical value for a single amino acid microelement chelate product and a compound amino acid / small-peptide microelement chelate product, therefore, the method has significance for promoting the development of a feed microelement additive industry and the publishing of relevant industrial standards.